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suggest that clinical isolates containing  embB 306 mutations 
with MICs overlapping the critical concentration are associ-
ated with discordant ethambutol susceptibility test results. 
The clinical significance of borderline resistance in combina-
tion treatment of tuberculosis remains to be determined be-
fore alternative ethambutol breakpoints are considered. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Ethambutol (EMB) inhibits arabinogalactan synthesis 
and resistance to EMB is associated with mutations in 
three genes involved in arabinogalactan synthesis termed 
 emb CAB  [1] . These genes are organized as a 10-kbp op-
eron, designated the EMB-resistance-determining re-
gion  [1] . The most frequent point mutations associated 
with EMB resistance occur at codon 306 in the  embB gene 
( embB 306)  [1–3] . Single nucleotide polymorphisms 
(SNPs) described in this codon are ATG  ]  GTG, CTG, 
ATA, ATC and ATT, resulting in three amino acid sub-
stitutions methionine (M) (ATG)  ]  valine (V) (GTG), 
leucine (L) (CTG) and isoleucine (I) (ATA; ATC; ATT) 
 [1,  3] . Allelic exchange experiments demonstrated that 
mutations at  emb B306 are associated with decreased sus-
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ceptibility to EMB  [2–4] . Sequence variation in  embB 306 
has therefore been proposed as a promising molecular 
marker to predict EMB resistance in  Mycobacterium tu-
berculosis  [2] . However, reports that mutations in 
 embB 306 were also present in EMB-susceptible strains 
question the reliability of this mutation as a reliable mark-
er of resistance  [5, 6] . 
 Disparity in phenotypic susceptibility results of EMB 
has widely been reported and various reasons have been 
linked to poor reproducibility  [1, 7, 8] . Among these are 
methodological variations, heteroresistance, and the 
likelihood that the narrow range between the minimum 
inhibitory concentrations (MICs) of wild-type and resis-
tant isolates give rise to borderline results  [2, 7–9] .
 The aim of this study was (1) to correlate mutations in 
the  embB gene at codon 306 with the MIC levels of EMB 
in clinical isolates of  M. tuberculosis and (2) to analyze 
the quantitative resistance and molecular data to clarify 
inconsistencies in routine EMB susceptibility test re-
sults.
 Materials and Methods 
 A total of 111 drug-resistant  M. tuberculosis clinical isolates 
were selected for study. The isolates were obtained from separate 
patients resident in the Western Cape, South Africa. Aliquots of 
stock cultures were prepared and kept under cryogenic conditions 
(–80   °   C). The resistance status of all isolates was confirmed by 
BACTEC TM 960 TM testing (Becton Dickinson Diagnostic Systems, 
Sparks, Md., USA) according to the standard critical concentra-
tions set by the World Health Organization  [10] . Fifty-two isolates 
were extensively drug-resistant (XDR), 47 were multidrug-resis-
tant (MDR), 10 were resistant to both isoniazid (INH) plus strep-
tomycin and two were resistant to INH. The genotypes of all se-
lected isolates were previously determined and categorized as typ-
ical Beijing (n = 31), atypical Beijing (n = 49)  [11] and Low Copy 
Clade (LCC; n = 31) strains  [12] . Within the typical Beijing group 
were 8 XDR and 23 MDR strains; the atypical Beijing family was 
comprised of 30 XDR, 17 MDR and 2 INH monoresistant strains. 
The LCC included 14 XDR, 7 MDR and 10 isolates that were re-
sistant to INH and streptomycin.
 All the isolates were screened for SNPs in a 240-bp region
of the  embB  gene, which encodes amino acids 271–350. This re-
gion was amplified by PCR with primer sets as previously de-
scribed  [13] : Emb151 (5  -CGGCATGCGCCGGCTGATTC-  3) 
and EmbB131 (5  -TCCACAGACTGGCGTCGCTG-  3). Ampli-
cons were sequenced with an ABI PRISM DNA sequencer (Ap-
plied Biosystems, Foster City, Calif., USA) and the resulting chro-
matograms were analyzed by the use of Chromas software (Tech-
nelysium Pty Ltd).
 The MICs for EMB were determined by quantitative drug sus-
ceptibility testing in BACTEC MGIT 960 eXtended individual 
Susceptibility Testing (TB eXiST) for EpiCenter TM V5.75A (BD 
Bioscience, Erembodegem, Belgium) as described  [14] . EMB (Sig-
ma-Aldrich, Kempton Park, South Africa) was prepared in sterile 
distilled water, filter-sterilized and stored at –80   °   C for up to 6 
months. All isolates were subjected to quantitative drug suscep-
tibility testing at EMB concentrations of 1.25, 2.5, 5.0, 12.5, 25.0 
and 50.0   g/ml. The interpretation of MIC values was based on 
the 1% proportional method. A critical concentration of 5.0   g/
ml was used to distinguish between EMB-susceptible and EMB-
resistant isolates  [10] .  M. tuberculosis  H37Rv (ATCC 27294) was 
included as a drug-susceptible reference strain for quality control 
purposes.
 Results 
 The distribution of  embB 306 mutations amongst 111 
clinical isolates of three different genotypes, together 
with sequence and quantitative drug susceptibility data, 
is presented in  tables 1 and  2 . Thirty-four (31%) of the 111 
isolates lacked  embB 306 mutations and 76% (26/34) of 
these exhibited EMB MICs of 1.25 to  ^  2.5   g/ml, which 
are below the standard critical concentration of 5.0   g/
ml  [10] ( tables 1 ,  2 ). The susceptibility levels of these iso-
lates were similar to those displayed by the susceptible  M. 
tuberculosis reference strain (H37Rv) confirming that 
they are genotypically and phenotypically susceptible to 
EMB. The 26 isolates were identified to be of the typical 
Beijing (n = 6), atypical Beijing (n = 4) and LCC (n = 16) 
genotypes. Amongst the 26 isolates were 2 XDR, 12 MDR, 
2 INH monoresistant and 10 INH plus streptomycin-re-
sistant strains. Eight of the 34 isolates that had no  embB 
 mutations showed phenotypic resistance to EMB exhibit-
ing MICs of  1 5.0 to  ^  12.5   g/ml (n = 1),  1 12.5 to  ^  25.0 
  g/ml (n = 6) and  1 25.0 to  ^  50.0   g/ml (n = 1). All 8 
isolates were typical Beijing strains and 4 were MDR and 
4 XDR.
 In comparison, 69% (77/111) of the test isolates had 
SNPs at  embB 306 with 4 different nucleotide substitu-
tions (ATG ] ATC, ATA, GTG and CTG) associated with 
decreased susceptibility to EMB. M306I substitutions oc-
curred as a result of nucleotide alterations at ATG ] ATC 
(n = 32) and ATG  ]  ATA (n = 24) in 56/77 (73%) isolates. 
Eighteen (23%) of the 77 isolates contained an M306V 
(ATG  ]  GTG) mutation and 3/77 (4%) had an M306L 
(ATG  ]  CTG) replacement ( table 1 ). Among the 77 mu-
tant isolates, 67 (87%) were phenotypic resistant and 10 
(13%) phenotypic susceptible to EMB as per critical con-
centration testing  [10] . The EMB MIC of the 10 isolates 
was equivalent to the critical concentration (5.0   g/ml) 
and 2- to 4-fold higher than those of the 26 susceptible 
wild-type isolates. Within the typical Beijing family 55% 
(17/31) had  embB 306 mutations, dominated by M306V 
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(88%; 15/17). Thirteen (87%; 13/15) M306V mutants had 
EMB MICs of  1 12.5 to  ^  25.0   g/ml and 2/15 exhibited 
MICs of  1 5.0 to  ^  12.5   g/ml and  1 25 to  ^  50   g/ml, 
respectively. Only 2/17 M306I mutations were detected 
among the typical Beijing isolates; one of them had an 
MIC of  1 5.0 to  ^  12.5   g/ml and the other one showed 
an MIC of  1 12.5 to  ^  25.0   g/ml. Among the atypical 
Beijing isolates, 92% (45/49) had SNPs in  embB 306 and of 
these 91% (41/45) possessed the M306I mutations, ATC 
(n = 23) and ATA (n = 18). The EMB MICs in 38/41 (93%) 
of these isolates were 5.0 to  ^  12.5   g/ml reflecting low-
level or intermediate resistance. Higher MICs ( 1 12.5 to 
 ^  25.0   g/ml) were demonstrated in only 3/41 (7%) of the 
atypical Beijing isolates with the M306I substitution 
(ATG ] ATC). The other four isolates within this geno-
type had M306V (n = 1) and M306L (n = 3) mutations 
with EMB MICs of  1 5.0 to  ^  12.5 and  1 12.5 to  ^  25   g/
ml, respectively.  embB 306 mutations were detected in 
48% (15/31) of the LCC isolates and 87% (13/15) of these 
harbored the M306I mutation, while the amino acid sub-
stitution M306V was present in 2/13 of the isolates. All 15 
LCC mutant isolates exhibited EMB MICs (5.0 to  ^  12.5) 
similar to those observed in most of the atypical Beijing 
strains.
Table 1. C orrelation of phenotypic and genotypic susceptibility data of EMB in different M. tuberculosis genotypes
Genotypes MIC
g/ml
Isolates with embB306 mutations (n = 77) Wild-type
embB306
isolatesM306I M306V M 306L
ATG]ATC ATG]ATA ATG]GTG ATG]C TG
Typical Beijing (n = 31) 1.25 to ≤2.5
5.0
>5 to ≤12.5
>12.5 to ≤25
>25 to ≤50
0
0
0
1
0
0
0
1
0
0
0
0
1
13
1
0
0
0
0
0
6
0
1
6
1
Atypical Beijing (n = 49) 1.25 to ≤2.5
5.0
>5.0 to ≤12.5
>12.5 to ≤25
>25 to ≤50
0
1
19
3
0
0
1
17
0
0
0
0
1
0
0
0
0
0
3
0
4
0
0
0
0
LCC (n = 31) 1.25 to ≤2.5
5.0
>5.0 to ≤12.5
>12.5 to ≤25
>25 to ≤50
0
5
3
0
0
0
2
3
0
0
0
1
1
0
0
0
0
0
0
0
16
0
0
0
0
n 32 24 18 3 34
Table 2. S ummary of EMB MICs compared to embB306 mutations detected in M. tuberculosis isolates
MIC
g/ml
I solates with embB306 mutations (n = 77) Wild-type
embB306
isolatesM306 I M306V M306L
ATG]ATC ATG]ATA ATG]GTG ATG]CTG
1.25 to ≤2.5 0 0 0 0 26
5.0 6 3 1 0 0
>5.0 to ≤12.5 22 21 3 0 1
>12.5 to ≤25 4 0 13 3 6
>25 to ≤50 0 0 1 0 1
n 32 24 18 3 34
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 Discussion 
 Amongst the 56 isolates with M306I substitutions, 
93% (52/56) had MICs equal or moderately above the crit-
ical concentration (MICs, 5.0 to  ^  12.5   g/ml). We sug-
gest that these borderline results account for the discor-
dance found among isolates that were genotypic resistant 
but phenotypic susceptible. This problem can be reduced 
by adjusting the current critical concentration or by in-
troducing two or multiple breakpoints, based on mea-
sures of quantitative drug susceptibility and genotypic 
testing. A susceptibility breakpoint of 4.0   g/ml for EMB 
has recently been suggested  [15] . This recommendation 
was based on a pharmacokinetic (PK) and pharmacody-
namic (PD) approach, but it failed to specify the relevant 
in vitro conditions for susceptibility testing for which this 
breakpoint is suitable  [15] . Using a reduced breakpoint to 
detect phenotypic resistance should improve the detec-
tion rate of mutants that confer low-level resistance to 
EMB. It is, however, important to introduce an assess-
ment scheme that identifies intermediate susceptible 
strains, based on the MIC distribution of EMB. Patients 
with moderately increased MICs may still benefit from 
treatment, especially in situations where therapeutic op-
tions are limited, since low-level (borderline) resistance 
does not necessarily imply clinical resistance.
 EMB has a rather narrow therapeutic index as a result 
of ocular toxicity which is dose-related  [16] . The standard 
recommended daily doses of EMB for adults are 15–20 
mg/kg body weight daily, or 3 times weekly at 25–35 mg/
kg body weight  [16] . A peak serum level of 5.0   g/ml is 
achieved following a dose of 25 mg/kg of EMB  [16] , which 
is equivalent to the MICs of low-level (or borderline) 
EMB-resistant isolates. EMB serum concentrations are 
dose related and 10   g/ml can be attained at a dose of 50 
mg/kg, but with an increased risk of patients developing 
ocular toxicity  [16] . The relation between PK and PD pa-
rameters (PK/PD index) is considered an important 
characteristic of drug efficacy  [15] . The PK/PD index for 
EMB according to the above-mentioned C max /MIC data 
reflects low therapeutic efficacy. Despite this, EMB re-
mains effective even at sub-MICs, as it has a synergistic 
effect when used with companion drugs  [10] . A thorough 
clinical assessment involving appropriate PK/PD param-
eters needs to be done to measure the clinical impact of 
decreased EMB susceptibility in particular on MDR and 
XDR tuberculosis (TB). 
 Using MIC values as a microbiological parameter can 
be misleading, since a critical concentration of 5.0   g/ml 
in MGIT 960 for EMB is equivalent to 2.0, 2.5, 5.0 and 
7.5   g/ml in Löwenstein-Jensen, BACTEC 460, 7H10 and 
7H11 media, respectively  [4, 10] . Previous studies dem-
onstrated that susceptibility testing of EMB on agar-
based medium can lead to underreporting of 50–91% of 
drug resistance compared with genotypic and radiomet-
ric BACTEC 460 testing  [2, 8, 9, 13] . Borderline resistance 
to EMB in clinical isolates was successfully detected in 
this study by quantitative drug susceptibility testing us-
ing MGIT 960 equipped with TB eXiST  [14] . This tech-
nology is thus recommended to become the standard for 
susceptibility testing of EMB, given that agar-based crit-
ical methods are unreliable.
 Fourteen (78%) of 18 isolates with the M306V muta-
tion had MICs  1 12,5   g/ml, which are well above the 
critical concentration. Only one isolate with this muta-
tion was phenotypic susceptible to EMB with an MIC of 
5.0   g/ml (borderline result), while three had moderate 
levels of resistance (MICs;  1 5.0 to  ^  12.5   g/ml). The 
M306L mutation was detected in only three isolates with 
resistance levels similar to those observed in the major-
ity of the M306V mutant isolates (MICs;  1 12.5 to  ^  25.0 
  g/ml). M306V and M306L were thus associated with 
higher levels of EMB resistance as opposed to those gen-
erated by the M306I substitution. Similar observations 
were made in previous studies  [1–3, 17, 18] , which also 
implied that M306L is less frequently found in  M. tuber-
culosis strains compared to M306I and M306V. Isolates 
that acquired either the M306I or M306V mutations had 
variable EMB MICs within a concentration range of 5.0–
50.0   g/ml. However, a fairly high proportion of isolates 
43/56 (77%) with the M306I mutation had MICs clus-
tered in a narrow interval ( 1 5 to  ^  12.5   g/ml) adjacent 
to the critical concentration of 5.0   g/ml. This interval 
was flanked by 16% (9/56) of the isolates with MICs 
equivalent to the critical concentration, while 7% (4/56) 
displayed higher levels of resistance ( 1 12.5 to  ^  25   g/
ml). Similarly, 72% (13/18) of the M306V mutants had 
MICs of  1 12.5 to  ^  25   g/ml, while 22% (4/13) were be-
low and 6% (1/18) above these concentrations. These data 
illustrate that the MIC distributions for EMB followed a 
typical gaussian pattern  [7] , suggesting that the majority 
of the isolates possessed a single mechanism of resis-
tance. The co-existence of other point mutations that 
were not investigated in this study could be the reason 
for higher levels of resistance. However, it has previously 
been shown that single  embB mutations are responsible 
for low to moderate levels of EMB resistance  [1, 3, 17, 19] . 
Based on this assumption, it has been anticipated that 
two or more independent mutations are needed to medi-
ate high-level EMB resistance in  M. tuberculosis  [19] . In 
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this study, a high proportion (56/77; 73%) of  embB mu-
tants had low to moderate levels of EMB resistance, 
which is additional evidence that single point mutations 
are the sole causative reason for resistance. The isolates 
with MICs above 12.5   g/ml were mainly associated 
with the M306V and M306L mutations, which are 
known to mediate higher levels of resistance  [1–3, 18] . 
Only one of these isolates had an MIC 5-fold higher than 
the critical concentration. Additional resistance mecha-
nisms or mutations could have been involved  [17, 19] in 
this case, but this study lacks information to confirm or 
exclude this possibility. Based on the above hypothesis 
and published evidence  [2, 3, 19] , it is unlikely that sec-
ondary mutations influenced the susceptibility levels of 
most of the clinical isolates that were quantified in this 
study. Decreased susceptibility in 8 isolates that lacked 
 embB 306 mutations points to the presence of sequence 
alterations elsewhere in the 10-kbp emb CAB operon or 
in other regions of the genome  [1–4, 17–22] . Alternative 
mechanisms or efflux  [23] , rather than genetic changes, 
may also contribute to decreased EMB susceptibility  [4, 
17, 19, 20] . The mechanisms responsible for EMB resis-
tance are diverse and complex  [4, 17–23] and need fur-
ther investigation to clarify the actual molecular basis of 
EMB resistance.
 M306I was the most frequently observed mutation 
(56/77) in this study, followed by M306V (18/77) and then 
M306L (3/77). M306I was more prevalent in the atypical 
Beijing (41/77) and LCC (13/77) genotypes and was main-
ly correlated with a lower level of EMB resistance (5 to 
 ^  12.5   g/ml). M306V were linked to typical Beijing iso-
lates, while M306L was relatively rare and found in 3 
atypical Beijing strains. The Beijing genotype has been 
associated with younger patients, which reveals a high 
transmission rate amongst individuals in this age group 
 [24] . Beijing isolates are also frequently associated with 
MDR TB and serious efforts should therefore be made to 
prevent its transmission  [24] . 
 Conclusion 
 Phenotypic and genotypic analyses demonstrated that 
 embB 306 mutations were reliable indicators of EMB sus-
ceptibility in a substantial proportion of 111 test isolates. 
These findings contradict the concept that EMB resis-
tance is a direct consequence of multiple-drug resistance 
due to  embB 306 mutations that predispose isolates to fa-
cilitate broad drug resistance  [6] . Instead, it is more like-
ly that following the development of drug resistance to 
the powerful antituberculosis compounds (INH and ri-
fampicin), subpopulations resistant to the less powerful 
EMB emerge due to increased selective pressure. Subther-
apeutic plasma concentrations of INH in patients with a 
rapid acetylator status could create selective pressure that 
may lead to treatment failure and the emergence of drug 
resistance  [25] . SNPs at  embB 306 displayed diverse MICs 
of which a significant proportion (73%) was scattered 
along the critical concentration resulting in borderline 
resistance. We conclude that borderline resistance can 
easily be missed by routine phenotypic drug susceptibil-
ity testing, hence false-susceptibility reporting. These 
data have clinical relevance and could be used to improve 
therapeutic strategies, especially in settings like the West-
ern Cape (South Africa) where drug-resistant TB is prob-
lematic. 
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